Your session is about to expire
← Back to Search
Cholinergic Agonist
OC-01 for Dry Eye Syndrome
Phase 2
Waitlist Available
Research Sponsored by Vance Thompson Vision - MT
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 0 (surgical day) and day 7 to day 28 (1-month postoperative cxl)
Awards & highlights
Summary
A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated study to Assess the Efficacy of OC-01 (varenicline) Nasal Spray on signs and symptoms of Dry Eye Disease in subjects following Corneal Collagen Crosslinking (CXL)
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to day 0 (surgical day) and day 7 to day 28 (1-month postoperative cxl)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 0 (surgical day) and day 7 to day 28 (1-month postoperative cxl)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Corneal Epithelial Healing
NEI VFQ-25 Questionnaire
Secondary study objectives
Adverse Events
Corneal Fluorescein Staining
Dryness Scoring
+1 moreSide effects data
From 2022 Phase 4 trial • 39 Patients • NCT0401128050%
Dysgeusia
50%
Anxiety
36%
Sleep Disturbances
29%
Nausea
21%
Agitation
21%
Depression
21%
Headache
14%
Heartburn
14%
Allergies
14%
Cold
14%
Back Pain
7%
Confusion
7%
Aggression
7%
Panic
7%
Stomach Pain
7%
Dizziness
7%
Fatigue
7%
Leg Spasms
7%
Sinusitis
7%
Angina
7%
Increased Blood Pressure
7%
Palpitations
7%
Cellulitis
7%
Rash
7%
Malaise
7%
Weight Gain
7%
Gum Disease
7%
Pharyngitis
7%
Leg Cramps
7%
Muscle Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Low Dose Varenicline
Standard Dose Varenicline
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: OC-01Experimental Treatment1 Intervention
(varenicline 1.2mg/ml) nasal spray
Group II: PlaceboPlacebo Group1 Intervention
(vehicle) nasal spray
Find a Location
Who is running the clinical trial?
Vance Thompson Vision - MTLead Sponsor
1 Previous Clinical Trials
20 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger